Triple-Drug cocktail shows promise for rare kidney cancers
NCT ID NCT04413123
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This study tests whether combining three drugs (cabozantinib, nivolumab, and ipilimumab) can safely slow or shrink advanced kidney cancers that are not the common clear-cell type. About 60 adults with cancers like papillary or chromophobe RCC that have spread will receive the combination. The goal is to see how many patients respond and how long the benefit lasts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHROMOPHOBE RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Brigham & Woman's Hospital
Boston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
UT Southwestern Medical
Dallas, Texas, 75390, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a blast of radiation make immunotherapy work better against kidney cancer?
- Can reprogrammed immune cells take on hard-to-treat kidney cancer?
- Robot surgeon takes on kidney and prostate operations
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- AI model aims to predict recovery after Kidney-Sparing surgery